Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by AGF Management Ltd.

AGF Management Ltd. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 53,342 shares of the biopharmaceutical company’s stock after purchasing an additional 4,749 shares during the quarter. AGF Management Ltd.’s holdings in Gilead Sciences were worth $4,111,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Bank Julius Baer & Co. Ltd Zurich increased its stake in Gilead Sciences by 98,797.6% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock worth $30,366,034,000 after acquiring an additional 393,607,491 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Gilead Sciences by 324.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after acquiring an additional 13,764,169 shares during the last quarter. Norges Bank acquired a new stake in Gilead Sciences during the fourth quarter worth $1,115,186,000. Moneta Group Investment Advisors LLC increased its stake in Gilead Sciences by 96,759.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock worth $868,046,000 after acquiring an additional 10,100,755 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Gilead Sciences by 70.6% during the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after acquiring an additional 6,410,047 shares during the last quarter. Institutional investors and hedge funds own 82.33% of the company’s stock.

Gilead Sciences Stock Down 0.3 %

GILD opened at $74.72 on Wednesday. The business’s 50-day simple moving average is $76.81 and its 200-day simple moving average is $77.38. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.20 and a current ratio of 1.34. Gilead Sciences, Inc. has a one year low of $72.87 and a one year high of $89.74. The stock has a market capitalization of $93.10 billion, a P/E ratio of 16.03, a price-to-earnings-growth ratio of 0.85 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. The business had revenue of $7.05 billion for the quarter, compared to analysts’ expectations of $6.81 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business’s revenue was up .1% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 6.76 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 64.38%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 1,501 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the transaction, the insider now owns 70,130 shares in the company, valued at approximately $5,399,308.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the transaction, the chief financial officer now owns 104,003 shares in the company, valued at approximately $8,320,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 1,501 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the transaction, the insider now owns 70,130 shares in the company, valued at approximately $5,399,308.70. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by insiders.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. Royal Bank of Canada cut their target price on Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating for the company in a research note on Tuesday. HSBC assumed coverage on Gilead Sciences in a research report on Wednesday, September 6th. They set a “reduce” rating and a $71.00 price target for the company. StockNews.com assumed coverage on Gilead Sciences in a research report on Thursday, October 5th. They set a “strong-buy” rating for the company. Barclays lowered their price target on Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, July 24th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Gilead Sciences in a report on Thursday, November 9th. They issued a “hold” rating and a $75.00 target price for the company. One analyst has rated the stock with a sell rating, ten have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $88.22.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.